We need stronger evidence for (or against) hepatocellular carcinoma surveillance
- PMID: 33465402
- DOI: 10.1016/j.jhep.2020.12.029
We need stronger evidence for (or against) hepatocellular carcinoma surveillance
Abstract
Current guidelines from EASL recommend that most patients with cirrhosis are offered surveillance for hepatocellular carcinoma (HCC), but fewer patients than expected actually receive it. The recommendation is based on observational studies and simulations, not randomised trials. In this opinion piece we argue that a randomised trial of HCC surveillance vs. no surveillance is necessary and feasible, and we believe that clinician and patient participation in HCC surveillance would be better if it were based on trial results demonstrating its value.
Keywords: Cancer; Epidemiology; Prevention; Screening.
Copyright © 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflict of interest The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment in
-
In search of an evidence base for HCC surveillance: Purity or pragmatism?J Hepatol. 2021 May;74(5):1025-1027. doi: 10.1016/j.jhep.2021.02.018. Epub 2021 Mar 22. J Hepatol. 2021. PMID: 33766443 No abstract available.
-
Before we can find an evidence base for HCC surveillance, we need to define our target demographic.J Hepatol. 2021 Dec;75(6):1494-1495. doi: 10.1016/j.jhep.2021.06.042. Epub 2021 Jul 6. J Hepatol. 2021. PMID: 34242695 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
